Eli Lilly has named a new CFO and replaced the head of its research and development arm, among other top management changes.
Company Treasurer Josh Smiley will become CFO on Jan. 1, replacing Derica Rice, who will be retiring. Dan Skovronsky, a senior vice-president, will become president of R&D arm Lilly Research Labs on June 1, 2018, replacing the retiring Jan Lundberg.
Additionally, Myles O'Neill will head up Lilly's manufacturing operations beginning next year, replacing Maria Crowe, who is also retiring.
Eli Lilly announced earlier this month that it will be streamlining its operations to focus more resources on developing new medicines and to improve its cost structure. Global workforce reductions, including those from a U.S. voluntary early retirement program, are expected to impact about 3,500 positions.
Read the press release